Abstracts tagged "gout"

Abstract Number: 1296 • 2018 ACR/ARHP Annual Meeting
A Novel Potent and Selective Urate Transporter 1 Inhibitor, NC-2700, with pH-Raising Effect on Low Urinary pH
Masuharu Hirano¹, Takafumi Muto¹, Toshitake Hirai², Promsuk Jutabha³, Naohiko Anzai⁴, Toru Horie⁵, Hitoshi Endou⁶ and Tomio Yamakawa⁷, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ³Dokkyo Medical University School of Medicine, Tochigi, Japan, ⁴Chiba University Graduate School of Medicine, Chiba, Japan, ⁵Dethree Res Lab Inc., Tsukuba, Japan, ⁶J-Pharma Co., Ltd., Yokohama, Japan, ⁷Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: In most patients with gout, renal underexcretion of uric acid is the main mechanism for hyperuricemia. However, for the risk of uric acid kidney…
Abstract Number: 2847 • 2018 ACR/ARHP Annual Meeting
Associations between Serum Uric Acid Level and Coronary Artery Disease
Patricia Kachur^1,2, Satish Tadepalli³, Sergey Kachur⁴ and Pramil Cheriyath³, ¹Rheumatolgy, Ochsner Foundation Hospital, New Orleans, LA, ²Internal Medicine, Ocala Regional Medical Center, Ocala, FL, ³Hackensack Meridian Health, Ocean Medical Center, Brick, NJ, ⁴Ocala Regional Medical Center, Ocala, FL
Title: Association between Serum Uric Acid Level and Coronary Artery DiseaseBackground/Purpose: Previous studies have shown an unclear relationship between serum uric acid (SUA) and coronary…
Abstract Number: 1132 • 2018 ACR/ARHP Annual Meeting
Diet Modification for Gout Patients: Effects on Gout Attacks and Risk Factors for Metabolic Syndrome
Michelle DiFiore¹, Maida Wong² and Juliana Chang³, ¹Internal Medicine, University of California, Irvine, School of Medicine, Orange, CA, ²Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA, ³UC Irvine Medical Center, Orange, CA
Background/Purpose: Gout affects 8 million individuals in the US and is prevalent among patients with metabolic syndrome. Although there are many medications to control gout…
Abstract Number: 1297 • 2018 ACR/ARHP Annual Meeting
Risk of Dementia in Patients with Gout and the Impact of Urate-Lowering Therapies: A Large Population-Based Cohort Study
Louise Crowley, Alyshah Abdul Sultan, Edward Roddy, Christian Mallen, Joanne Protheroe and Lorna Clarson, Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom
Background/Purpose: Evidence is conflicting concerning dementia risk in gout patients, with hyperuricaemia proposed to exert a neuroprotective effect. Serum urate (sUA) targets guiding urate-lowering therapies…
Abstract Number: 2964 • 2018 ACR/ARHP Annual Meeting
Detection of Uric Acid Crystals in the Vasculature of Patients with Gout Using Dual-Energy Computed Tomography
Sharon Barazani¹, WeiWei Chi², Renata Pyzik³, Adam Jacobi⁴, Tom O'Donnell⁵, Zahi Fayad³, Venkatesh Mani³ and Yousaf Ali², ¹Medical School, Icahn School of Medicine at Mount Sinai, New York, NY, ²Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Translational and Molecular Imaging Institute (TMII), Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Siemens Healthcare, New York, NY
Background/Purpose: Many recent studies have shown an association between gout and increased cardiovascular risk, however the mechanism by which this occurs is unclear. Dual-Energy Computed…
Abstract Number: 1204 • 2018 ACR/ARHP Annual Meeting
Experience Matters in Ultrasound Assessment of Gout
Burak Elkiran¹ and Eugene Y. Kissin², ¹Internal Medicine, Steward Carney Hospital, Boston, MA, ²Rheumatology, Boston University, Boston, MA
Background/Purpose: Ultrasound has emerged in the field of rheumatology as a diagnostic aid for gout and other similar forms of arthritis. While a number of…
Abstract Number: 1298 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Parkinson’s Disease in Older Adults: A Study of U.S. Medicare Data
Jasvinder A. Singh and John Cleveland, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: In the presence of limited available data, our objective was to assess the association of gout with the risk of incident Parkinson’s disease (PD)…
Abstract Number: 2965 • 2018 ACR/ARHP Annual Meeting
Targeting Glucose Metabolism in the Murine Air Pouch Model of Acute Gouty Inflammation
Anyan Cheng¹, Roxana Coras^1,2, Robert Terkeltaub^3,4, Ru Liu-Bryan^1,3 and Monica Guma^1,2, ¹Medicine, University of California San Diego, La Jolla, CA, ²Medicine, Autonomous University of Barcelona, Bellatera, Spain, ³VA San Diego Healthcare System, San Diego, CA, ⁴Medicine, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA
Background/Purpose: Emerging evidence indicates that macrophage activation is critically supported by glucose metabolic shifts. Although macrophages are key contributors to inflammation, little is known about…
Abstract Number: 197 • 2018 ACR/ARHP Annual Meeting
Improving Clinical Decisions for Gout Management: Effect of Online Case-Based Education
Nimish Mehta, Piyali Chatterjee-Shin and Karen Badal, Medscape, LLC, New York, NY
Background/Purpose: Gout is a chronic condition with a considerable effect on patient health and quality of life. Despite the availability of multiple pharmacologic treatments and…
Abstract Number: 1247 • 2018 ACR/ARHP Annual Meeting
Pharmacist-Managed Titration of Urate-Lowering Therapy to Streamline Gout Management
Irvin Huang¹, Jean Liew², Meredith Barnes³, Silu Zuo⁴, Carol Crawford⁴ and Alison Bays⁵, ¹Internal Medicine, Boise VAMC, Boise, ID, ²Internal Medicine; Division of Rheumatology, University of Washington, Seattle, WA, ³Medicine, University of Washington, Seattle, WA, ⁴Harborview Medical Center, Seattle, WA, ⁵Division of Rheumatology, University of Washington, Seattle, CA
Background/Purpose: The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines.…
Abstract Number: 2217 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Early Onset Gout in Outpatient Setting
Yan Li¹, Paramarajan Piranavan¹, Devi Sundaresan² and Robert A. Yood³, ¹Internal Medicine, St. Vincent Hospital, Worcester, MA, ²Research, Reliant Medical Group, Worcester, MA, ³Reliant Medical Group, Worcester, MA
Background/Purpose: There has been an increase in the prevalence of gout over the past two decades, with increasing number of patients presenting at younger age.…
Abstract Number: 2966 • 2018 ACR/ARHP Annual Meeting
Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Hilde B Hammer¹, Lars Fritjof Karoliussen², Lene Terslev³, Espen A. Haavardsholm¹, Tore Kvien⁴ and Till Uhlig⁵, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Rigshospitalet Glostrup, Copenhagen, Denmark, ⁴RAID working group for EULAR, Zurich, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Uric monosodium urate (MSU) depositions are detected by ultrasound (US), and US is included in the ACR/EULAR classification criteria for gout. OMERACT definitions for…
Abstract Number: 268 • 2018 ACR/ARHP Annual Meeting
The Effect of Renaming Gout to Urate Crystal Arthritis on Illness and Treatment Perceptions in Māori (the Indigenous People of Aotearoa/New Zealand)
Nicola Dalbeth¹, Meihana Douglas¹, Kate MacKrill¹, Leanne Te Karu², Maria Kleinstäuber¹ and Keith Petrie¹, ¹University of Auckland, Auckland, New Zealand, ²Ngā Kaitiaki o Te Puna Rongoā o Aotearoa, Taupō, New Zealand
Background/Purpose: Recent research has suggested that renaming gout to a pathophysiological illness label (urate crystal arthritis) avoids inaccurate lay perceptions of gout and promotes…
Abstract Number: 1260 • 2018 ACR/ARHP Annual Meeting
Predictors of Hospitalization Due to Acute Gout: A Retrospective Cohort Study
Nadine Mbuyi¹, Isha Shah², Steven Reinert³, Grayson Baird⁴, Pieusha Malhotra⁵, Ross Hilliard⁶ and Deepan Dalal⁷, ¹Rheumatology, The Warren Alpert Medical School of Brown University, Providence, RI, ²Internal Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, ³Lifespan Information Services, Lifespan Information Services, Providence, RI, Providence, RI, ⁴Department of Biostatistics, Lifespan, Rhode Island Hospital, Providence, RI, ⁵Rheumatology, Roger William Medical Center, Providence, RI, Providence, RI, ⁶Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, ⁷Medicine/Rheumatology, The Warren Alpert Medical School of Brown University, Providence, RI
Background/Purpose: Despite effective treatments, hospitalization due to acute gout is increasing and is financially burdensome. Prior studies have primarily attributed the increased rate of gout…
Abstract Number: 2219 • 2018 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
Masuharu Hirano¹, Shiro Kobayashi², Eri Miyayama², Takashi Ohta¹, Masao Yamamoto² and Tomio Yamakawa³, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Development Planning Department, Nippon Chemiphar Co., Ltd., Chiyoda-ku, Tokyo, Japan, ³Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: Gout flare due to rapid urate reduction after initiating urate-lowering therapy (ULT) is one of the major issues in the therapy. International guidelines recommend…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].